Neuromuscular therapeutics by RNA-targeted suppression of ACHE gene expression

Annals of the New York Academy of Sciences

Volumn 1082, Issue , 2006, Pages 77-90

  Dori, Amir ^a   Soreq, Hermona ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Anticholinergic treatment; Antisense treatment; Myasthenia gravis; Neuromuscular junction; Readthrough acetylcholinesterase

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; DIISOPROPYL FLUOROPHOSPHATASE; EN 101; EN 102; INTERLEUKIN 1; INTERLEUKIN 6; MONARSEN; PREDNISONE; PYRIDOSTIGMINE; RNA;

ANTIINFLAMMATORY ACTIVITY; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG STRUCTURE; DRUG TARGETING; ENTEROPATHY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MONKEY; EXPERIMENTAL RAT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HYDROLYSIS; INFLAMMATION; LOW DRUG DOSE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NERVE CELL; NEUROMUSCULAR DISEASE; NONHUMAN; PARTICLE SIZE; PERSIAN GULF SYNDROME; STEROID THERAPY; TOXICOLOGY; VOLUNTEER;

ANIMALIA; MACACA FASCICULARIS;

EID: 33845673318     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1348.004     Document Type: Conference Paper

References (66)

1. SILMAN, I. & J.L. SUSSMAN. 2005. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr. Opin. Pharmacol. 5: 293-302.
2. IMPERATO, A., S. PUGLISI-ALLEGRA, P. CASOLINI & L. ANGELUCCI. 1991. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res. 538: 111-117.
3. ENNIS, M. & M.T. SHIPLEY. 1992. Tonic activation of locus coeruleus neurons by systemic or intracoerulear microinjection of an irreversible acetylcholinesterase inhibitor: increased discharge rate and induction of C-fos. Exp. Neurol. 118: 164-177.
4. KAUFER, D., A. FRIEDMAN, S. SEIDMAN & H. SOREQ. 1998. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393: 373-377.
5. LEV-LEHMAN, E., T. EVRON, R.S. BROIDE, et al. 2000. Synaptogenesis and myopathy under acetylcholinesterase overexpression. J. Mol. Neurosci. 14: 93-105.
6. BAUSERO, P., M. SCHMITT, J.L. TOUSSAINT, et al. 1993. Identification and analysis of the human choline acetyltransferase gene promoter. Neuroreport 4: 287-290.
7. CERVINI, R., L. HOUHOU, P.F. PRADAT, et al. 1995. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 270: 24654-24657.
8. MESHORER, E., D. TOIBER, D. ZUREL, et al. 2004. Combinatorial complexity of 5′ alternative acetylcholinesterase transcripts and protein products. J. Biol. Chem. 279: 29740-29751.
9. SOREQ, H. & S. SEIDMAN. 2001. Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci. 2: 294-302.
10. LI, Y., S. CAMP, T.L. RACHINSKY, et al. 1991. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J. Biol. Chem. 266: 23083-23090.
11. MESHORER, E. & H. SOREQ. 2006. Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci. 29: 216-224.
12. MESHORER, E., B. BRYK, D. TOIBER, et al. 2005. SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol. Psychiatry. 10: 985-997.
13. KAUFER, D. & H. SOREQ. 1999. Tracking cholinergic pathways from psychological and chemical stressors to variable neurodeterioration paradigms. Curr. Opin. Neurol. 12: 739-743.
14. MESHORER, E., C. ERB, R. GAZIT, et al. 2002. Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 295: 508-512.
15. FARCHI, N., H. SOREQ & B. HOCHNER. 2003. Chronic acetylcholinesterase overexpression induces multilevelled aberrations in mouse neuromuscular physiology. J. Physiol. 546: 165-173.
16. COHEN, O., C. ERB, D. GINZBERG, et al. 2002. Neuronal overexpression of "readthrough" acetylcholinesterase is associated with antisense-suppressible behavioral impairments. Mol. Psychiatry 7: 874-885.
17. MCEWEN, B.S. 1999. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 22: 105-122.
18. SAPOLSKY, R.M., L.M. ROMERO & A.U. MUNCK. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21: 55-89.
19. MEZEY, G. & I. ROBBINS. 2001. Usefulness and validity of post-traumatic stress disorder as a psychiatric category. Br. Med. J. 323: 561-563.
20. SKLAN, E.H., A. LOWENTHAL, M. KORNER, et al. 2004. Acetylcholinesterase/ paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study. Proc. Natl. Acad. Sci. USA 101: 5512-5517.
21. GRIFMAN, M., N. GALYAM, S. SEIDMAN & H. SOREQ. 1998. Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis. Proc. Natl. Acad. Sci. USA 95: 13935-13940.
22. DRACHMAN, D.B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797-1810.
23. ROPPER, A.H. & R.H. BROWN. 2005. Adams and Victor's Principles of Neurology, 8th ed. McGraw-Hill. New York.
24. GRIFMAN, M. & H. SOREQ. 1997. Differentiation intensifies the susceptibility of pheochromocytoma cells to antisense oligodeoxynucleotide- dependent suppression of acetylcholinesterase activity. Antisense Nucleic Acid Drug Dev. 7: 351-359.
25. GRISARU, D., E. LEV LEHMAN, M. SHAPIRA, et al. 1999. Human osteogenesis involves differentiation-dependent increases in the morphogenically active 3′ alternative splicing variant of acetylcholinesterase. Mol. Cell. Biol. 19: 788-795.
26. GALYAM, N., D. GRISARU, M. GRIFMAN, et al. 2001. Complex host cell responses to antisense suppression of ACHE gene expression. Antisense Nucleic Acid Drug Dev. 11: 51-57.
27. BRENNER, T., Y. HAMRA-AMITAY, et al. 2003. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. Faseb J. 17: 214-22.
28. DORI, A., J. COHEN, W.F. SILVERMAN, et al. 2005. Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. Cereb. Cortex 15: 419-430.
29. EVRON, T., L.B. MOYAL-SEGAL, N. LAMM, et al. 2005. RNA-targeted suppression of stress-induced allostasis in primate spinal cord neurons. Neurodegenerative Dis. 2: 16-27.
30. BIRIKH, K.R., E.H. SKLAN, S. SHOHAM & H. SOREQ. 2003. Interaction of "readthrough" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior. Proc. Natl. Acad. Sci. USA 100: 283-288.
31. NIJHOLT, I., N. FARCHI, M. KYE, et al. 2004. Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation. Mol. Psychiatry 9: 174-183.
32. GRISARU, D., V. DEUTSCH, M. SHAPIRA, et al. 2001. ARP, a peptide derived from the stress-associated acetylcholinesterase variant, has hematopoietic growth promoting activities. Mol. Med. 7: 93-105.
33. PERRY, C., E.H. SKLAN & H. SOREQ. 2004. CREB regulates AChE-R-induced proliferation of human glioblastoma cells. Neoplasia 6: 279-286.
34. SOREQ, H., R. BEN AZIZ, C.A. PRODY, et al. 1990. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc. Natl. Acad. Sci. USA 87: 9688-9692.
35. CHAN, R.Y., F.A. ADATIA, A.M. KRUPA & B.J. JASMIN. 1998. Increased expression of acetylcholinesterase T and R transcripts during hematopoietic differentiation is accompanied by parallel elevations in the levels of their respective molecular forms. J. Biol. Chem. 273: 9727-9733.
36. SCHWARZ, M., Y. LOEWENSTEIN LICHTENSTEIN, D. GLICK, et al. 1995. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. Brain Res. Mol. Brain Res. 31: 101-110.
37. RAY, D.E. & P.G. RICHARDS. 2001. The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicol. Lett. 120: 343-351.
38. HALEY, R.W., S. BILLECKE & B.N. LA DU. 1999. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 157: 227-233.
39. VINCENT, A. 1999. Immunology of the neuromuscular junction and presynaptic nerve terminal. Curr. Opin. Neurol. 12: 545-551.
40. MONIA, B.P. 1997. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found Symp. 209: 107-119, discussion 119-23.
41. ENGEL, A.G., E.H. LAMBERT & T. SANTA. 1973. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology 23: 1273-1281.
42. HUDSON, C.S., J.E. RASH, TN. TIEDT & E.X. ALBUQUERQUE. 1978. Neostigmine-induced alterations at the mammalian neuromuscular junction II. Ultrastructure. J. Pharmacol. Exp. Ther. 205: 340-356.
43. CZURA, C.J. & K.J. TRACEY. 2005. Autonomic neural regulation of immunity. J. Intern. Med. 257: 156-166.
44. TRACEY, K.J. 2002. The inflammatory reflex. Nature 420: 853-859.
45. WANG, H., M. YU, M. OCHANI, et al. 2003. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388.
46. LI, Y., L. LIU, J. KANG, et al. 2000. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J. Neurosci. 20: 149-155.
47. TAVITIAN, B., S. TERRAZZINO, B. KUHNAST, et al. 1998. In vivo imaging of oligonucleotides with positron emission tomography. Nat. Med. 4: 467-471.
48. HELLSTROM-LINDAHL, E., O. GORBOUNOVA, A. SEIGER, et al. 1998. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res. Dev. Brain Res. 108: 147-160.
49. SHYTLE, R.D., T. MORI, K. TOWNSEND, et al. 2004. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89: 337-343.
50. BAN, E., F. HAOUR & R. LENSTRA. 1992. Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administration. Cytokine 4: 48-54.
51. QUAN, N., S.K. SUNDAR & J.M. WEISS. 1994. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J. Neuroimmunol. 49: 125-134.
52. PITOSSI, F., A. DEL REY, A. KABIERSCH & H. BESEDOVSKY. 1997. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J. Neurosci. Res. 48: 287-298.
53. NGUYEN, K.T., T. DEAK, S.M. OWENS, et al. 1998. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J. Neurosci. 18: 2239-2246.
54. TURRIN, N.P., D. GAYLE, S.E. ILYIN, et al. 2001. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull. 54: 443-453.
55. EK, M., M. KUROSAWA, T. LUNDEBERG & A. ERICSSON. 1998. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J. Neurosci. 18: 9471-9479.
56. POLLAK, Y., A. GILBOA, O. BEN-MENACHEM, et al. 2005. Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann. Neurol. 57: 741-745.
57. BRADLEY, W.G., R.B. DAROFF, G.M. FENICHEL & J. JANKOVIC. 2004. Neurology in Clinical Practice. Elsevier. Philadelphia.
58. THOMAS, C.E., S.A. MAYER, Y. GUNGOR, et al. 1997. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48: 1253-1260.
59. PASCUZZI, R.M., H.B. COSLETT & T.R. JOHNS. 1984. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann. Neurol. 15: 291-298.
60. SHAPIRA, M., I. TUR-KASPA, L. BOSGRAAF, et al. 2000. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum. Mol. Genet. 9: 1273-1281.
61. GRISARU, D., M. PICK, C. PERRY, et al. 2006. Hydrolytic and nonenzymatic functions of acetylcholinesterase comodulate hemopoietic stress responses. J. Immunol. 176: 27-35.
62. KANAORI, K., S. SAKAMOTO, H. YOSHIDA, et al. 2004. Effect of phosphorothioate chirality on i-motif structure and stability. Biochemistry 43: 5672-5679.
63. GEARY, R.S., T.A. WATANABE, L. TRUONG, et al. 2001. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol. Exp. Ther. 296: 890-897.
64. OPALINSKA, J.B. & A.M. GEWIRTZ. 2002. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1: 503-514.
65. KRIEG, A.M. 2004. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6: 88-95.
66. GUIMARAES-STERNBERG, C., A. MEERSON, I. SHAKED & H. SOREQ. 2006. MicroRNA modulation of megakaryoblast fate involves cholinergic signaling. Leuk. Res. 30: 583-595.